Clinical Trial Update: Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the combination of tislelizumab and S-1 for patients with postoperative recurrent high-risk intrahepatic cholangiocarcino…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• S-1 (tegafur/gimeracil/oteracil)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Anhui Provincial Hospital | Conditions: Intrahepatic Cholangiocarcinoma | Phase 2 | Status: RECRUITING